CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Sociedade Beneficente de Senhoras (SBSHSL). Hospital Sírio-Libanês (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduation at Ciências Biológicas from Universidade de São Paulo (1994) and doctorate at Parasitology from Universidade de São Paulo (1997). Has experience in Genetics, focusing on Human and Medical Genetics, acting on the following subjects: cancer, metilação, expressão gênica, câncer and adam23. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Un método distinto |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Recent data indicates that the autonomic nervous system, comprising the sympathetic and parasympathetic divisions, significantly contributes to the initiation and progression of cancer, thereby adversely affecting the patient's prognosis. It functions as a facilitator within the tumor microenvironment, promoting its growth and development. For instance, the sympathetic nervous system play…
Despite of the uninterrupted development of new medications for the treatment of cancer, the survival rate continues low especially in those patients in the advanced stage of the disease. Recent observations show that new therapeutics increase the susceptibility for cardiovascular diseases, which turns out to be the treatment of cancer even more complex. Cardiac dysfunction due to cardiot…
(Only some records are available in English at this moment)
Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (NMIBC) accounts for 70-80% of all Bladder Cancer initial diagnoses. The standard treatment for NMIBC involves transurethral resection of the tumor, followed by intravesical immunotherapy with BCG. The clinical benefits of BCG therapy have been extensively documented. However, only 50% of the patients have long-lasting benefit, where…
In the last decades, there has been a remarkable progress in the treatment of different types of cancer, which has improved the prognosis of patients with this disease. Despite this, cancer remains the second leading cause of death in the world and it is also the leading cause of death in developed countries. Therefore, strategies capable of attenuating tumor initiation, progression and a…
The Epidermal Growth Factor Receptor (EGFR) was the first receptor to be proposed as a target for cancer therapy after two decades of intense research. Anti-EGFR therapies are used in the clinic to treat different types of cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer (CCR). The tyrosine kinase inhibitors - Gefitinib and Erlotinib - are used to treat NSCLC, a…
(Only some records are available in English at this moment)
Monitoring and detection of genetic changes associated with acquired resistance to anti-EGFR therapy in ctDNA from patients with lung and colon cancerThe Epidermal Growth Factor Receptor (EGFR) was the first receptor to be proposed as a target for cancer therapy after two decades of intense research. Anti-EGFR therapies are used in the clinic to treat non-small cell lung cancer (NSCLC) an…
Aneuploidy, an abnormal balance of chromosomes, is a common feature of solid tumors and is resulting from errors in chromosome segregation. Whether aneuploidy promotes or suppresses tumor initiation and progression is a controversial question, and the identification of new molecular mechanisms that underlie the chromosome segregation is relevant to our full understanding of genetic stabil…
The oncogene ErbB2/HER2 is overexpressed in roughly 30% of all breast tumors and is directly associated with rapid disease progression and poor prognosis, although its molecular mechanisms remain to be better understood. Transcriptional changes associated with the overexpression of ErbB2 in human breast tumors were investigated in our group using an immortalized mammary epithelial cell (H…
| 1 / 1 | Ongoing grants |
| 9 / 4 | Completed research grants |
| 35 / 11 | Completed scholarships in Brazil |
| 3 / 3 | Completed scholarships abroad |
| 48 / 19 | All research grants and scholarships |
| Associated processes | |